Phase II trial of mitoxantrone in multiple myeloma: A southwest oncology group study

D. S. Alberts, S. P. Balcerzak, J. D. Bonnet, R. L. Stephens

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Thirty-five fully evaluable patients with advanced multiple myeloma, refractory to standard chemotherapeutic agents, were entered into a phase II trial with mitoxantrone at a starting dose of 12 mg/m2 iv every 3 weeks. There was one (3%) partial response (lasting 2 1/2 months) in a patient who had received treatment with five different agents, including doxorubicin (total dose, 150 mg/m2). Four additional patients (11%) showed objective evidence of clinical improvement, lasting 4-7 months. Mitoxantrone was well-tolerated with no drug-induced deaths and only moderate to severe leukopenia as the dose-limiting toxicity in the majority of patients. Although mitoxantrone had a low level of activity in this heavily pretreated patient population, consideration should be given to future trials incorporating mitoxantrone into a new drug combination.

Original languageEnglish (US)
Pages (from-to)1321-1323
Number of pages3
JournalCancer Treatment Reports
Volume69
Issue number11
StatePublished - Dec 1 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of mitoxantrone in multiple myeloma: A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this

    Alberts, D. S., Balcerzak, S. P., Bonnet, J. D., & Stephens, R. L. (1985). Phase II trial of mitoxantrone in multiple myeloma: A southwest oncology group study. Cancer Treatment Reports, 69(11), 1321-1323.